Growth • Pacira BioSciences
PCRX
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
10,7%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
22,3%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
0%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
0%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
29,9%
CAGR Normalized EPS 5Y
Normalized Earnings Per Share Compound Annual Growth Rate in the last 5 years.
21,8%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!